Publications by authors named "Debora Luzi"

Claim this Profile
M
Mechanobiology and Primary Cilium in the Pathophysiology of Bone Marrow Myeloproliferative Diseases.
Federica Tiberio, Anna Rita Daniela Coda, Domiziano Dario Tosi, Debora Luzi, Luca Polito

Int J Mol Sci· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
Mario Tiribelli, Roberto Latagliata, Massimo Breccia, Isabella Capodanno, Maria Cristina Miggiano, Debora Luzi

Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
Massimo Breccia, Elisabetta Abruzzese, Vincenzo Accurso, Immacolata Attolico, Sara Barulli, Debora Luzi

Br J Haematol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study.
Beatrice Casadei, Lisa Argnani, Alessandro Broccoli, Caterina Patti, Piero Maria Stefani, Debora Luzi

Cancers (Basel)· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
Giovanni Caocci, Olga Mulas, Isabella Capodanno, Massimiliano Bonifacio, Mario Annunziata, Debora Luzi

Ann Hematol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors.
Roberto Latagliata, Immacolata Attolico, Malgorzata Monika Trawinska, Isabella Capodanno, Mario Annunziata, Debora Luzi

Hematol Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
Olga Mulas, Giovanni Caocci, Fabio Stagno, Massimiliano Bonifacio, Mario Annunziata, Debora Luzi

Ann Hematol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study.
Giovanni Caocci, Olga Mulas, Isabella Capodanno, Elisabetta Abruzzese, Alessandra Iurlo, Debora Luzi

Blood Cancer J· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.
Massimo Breccia, Elisabetta Abruzzese, Fausto Castagnetti, Massimiliano Bonifacio, Domenica Gangemi, Debora Luzi

Ann Hematol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution.
Lorenzo Falchi, Giovanna Rege-Cambrin, Carmen Fava, Emilio Donti, Debora Luzi

Cancer Genet Cytogenet· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy.
Alberto Patriti, Emanuel Cavazzoni, Luigina Graziosi, Antonio Pisciaroli, Debora Luzi

Surg Laparosc Endosc Percutan Tech· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis